Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.113979 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Liangshun You und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of Ch…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Leukopenia, Sulfonamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China; Zhejiang Provincial Clinical Research Center for Hematologic Dise…
- The First People's Hospital of Taizhou, Huangyan District, Zhejiang China.
Zitieren
APA
You, L., Liu, Y., Mai, W., Xie, W., Zhou, Mao, L., Chen, L., Zhou, X., Ma, L., Zheng, X., Wei, J., Lou, Y., Ye, X., Tong, H., Jin, J., & Meng, H. (2024). Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113979
Vancouver
You L, Liu Y, Mai W, Xie W, Zhou, Mao L, et al. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113979
BibTeX
@article{You2024,
author = {You, Liangshun and Liu, Yi and Mai, Wenyuan and Xie, Wanzhuo and Zhou, De and Mao, Liping and Chen, Lili and Zhou, Xinping and Ma, Liya and Zheng, Xiaolong and Wei, Juying and Lou, Yinjun and Ye, Xingnong and Tong, Hongyan and Jin, Jie and Meng, Haitao},
title = {Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.113979}
}
EUVIMED